Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 120

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 120
---
 Company’s consolidated results of operations, financial position, or cash flows. The Company does not enter into arrangements to hedge its currency risk exposure, although it maintains expected Canadian dollar cash requirements in Canadian dollars to form a natural hedge. The Company is exposed to currency risk through its cash, other current receivables, accounts payable, accrued expenses and other current liabilities, as well as right-of-use lease liabilities denominated in Canadian dollars as follows: 

        December 31,

        2024

        2023

        (in thousands)

        Cash
         
        $
        1,481

        $
        3,120

        Other current receivables

        486

        743

        Accounts payable

        (112
        )

        (290
        )

        Accrued expenses and other current liabilities

        (2,374
        )

        (4,310
        )

        Lease liabilities

        (1,216
        )

        (2,971
        )

        Net financial position exposure
         
        $
        (1,735
        )
         
        $
        (3,708
        )
       
      Based on the above net exposure at December 31, 2024, and assuming that all other variables remain constant, a 10% depreciation of the U.S. dollar against the Canadian dollar would result in an increase of $0.1 million in the Company’s net loss for the year ended December 31, 2024.

135

21. Segment InformationThe Company operates and manages its business as a single reporting and operating segment, which is the research and development of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The Company's CODM is the Chief Executive Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is reported on the consolidated statement of operations and comprehensive loss. Managing and allocating resources on a consolidated basis enables to CODM to assess the overall level of resources available and how to be deploy these resources across functions and programs that are in line with the Company's long-term company-wide strategic goals. The following table presents reportable segment net loss, including significant expense categories, attributable to the Company's reportable segment for the years ended December 31, 2024 and 2023. 

        December 31,

        2024

        2023

        (in thousands)

        Revenue:

        Collaboration agreements
         
        $